[go: up one dir, main page]

SV2017005602A - Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso - Google Patents

Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso

Info

Publication number
SV2017005602A
SV2017005602A SV2017005602A SV2017005602A SV2017005602A SV 2017005602 A SV2017005602 A SV 2017005602A SV 2017005602 A SV2017005602 A SV 2017005602A SV 2017005602 A SV2017005602 A SV 2017005602A SV 2017005602 A SV2017005602 A SV 2017005602A
Authority
SV
El Salvador
Prior art keywords
drospirenone
female patient
excess weight
patient affected
based contraceptive
Prior art date
Application number
SV2017005602A
Other languages
English (en)
Inventor
Dominique Drouin
Cecile Bouyer-Joubert
Philippe Perrin
Original Assignee
Laboratorios Leon Farma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56178376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15305965.4A external-priority patent/EP3108889A1/en
Priority claimed from CN201510348953.1A external-priority patent/CN106265694A/zh
Application filed by Laboratorios Leon Farma S A filed Critical Laboratorios Leon Farma S A
Publication of SV2017005602A publication Critical patent/SV2017005602A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA DROSPIRENONA COMO EL ÚNICO INGREDIENTE ANTICONCEPTIVO COMPRENDIDO EN UNA UNIDAD DE DOSIFICACIÓN DIARIA ACTIVA EN UNA CANTIDAD DE AL MENOS 3 MG PARA SU USO COMO ANTICONCEPTIVO PARA UNA PACIENTE MUJER CON AFECCIÓN DE OBESIDAD.
SV2017005602A 2015-06-23 2017-12-21 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso SV2017005602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305965.4A EP3108889A1 (en) 2015-06-23 2015-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight
CN201510348953.1A CN106265694A (zh) 2015-06-23 2015-06-23 用于过重女性患者的基于屈螺酮的避孕药

Publications (1)

Publication Number Publication Date
SV2017005602A true SV2017005602A (es) 2018-08-14

Family

ID=56178376

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005602A SV2017005602A (es) 2015-06-23 2017-12-21 Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso

Country Status (26)

Country Link
EP (1) EP3313408B1 (es)
JP (1) JP6827962B2 (es)
KR (1) KR102217942B1 (es)
CN (2) CN113750108B (es)
AU (1) AU2016282863B2 (es)
BR (1) BR112017028048A2 (es)
CA (1) CA2989975C (es)
DK (1) DK3313408T3 (es)
EA (1) EA036497B1 (es)
ES (1) ES2970532T3 (es)
FI (1) FI3313408T3 (es)
HR (1) HRP20240121T8 (es)
HU (1) HUE065350T2 (es)
LT (1) LT3313408T (es)
MX (1) MX389310B (es)
MY (1) MY187233A (es)
NI (1) NI201700173A (es)
PH (1) PH12017502379A1 (es)
PL (1) PL3313408T3 (es)
RS (1) RS65196B1 (es)
SI (1) SI3313408T1 (es)
SM (1) SMT202400062T1 (es)
SV (1) SV2017005602A (es)
UA (1) UA122873C2 (es)
WO (1) WO2016207298A1 (es)
ZA (1) ZA201800067B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
CA2988362C (en) 2015-06-18 2022-07-19 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CN107787224A (zh) 2015-06-18 2018-03-09 密特拉制药公司 含雌四醇组分的口腔分散剂量单位
CA2989975C (en) 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
CN1950092A (zh) * 2004-04-30 2007-04-18 舍林股份公司 对延长的激素避孕方案中突破性出血的控制
JP5288796B2 (ja) * 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
DK1746101T4 (da) 2005-07-21 2014-08-11 Bayer Pharma AG Fremgangsmåde til fremstilling af 3-oxo-pregn-4-en-21,17-carbolactoner ved metalfri oxidation af 17-(3-hydroxypropyl)-3,17-dihydroxyandrostaner
AU2008235006A1 (en) * 2007-04-05 2008-10-16 Bayer Schering Pharma Aktiengesellschaft New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
EP2548881B1 (en) * 2010-03-16 2014-12-17 Taizhou Taifa Pharmaceuticals Co., Ltd Preparation method of drospirenone
RU2422824C1 (ru) * 2010-05-07 2011-06-27 Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи Способ выбора тактики лечения нарушений менструального цикла у девочек-подростков с избыточной массой тела
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CN103372015A (zh) * 2012-04-19 2013-10-30 国家人口计生委科学技术研究所 包含屈螺酮或屈螺酮和雌激素的阴道环制剂
RU2527357C1 (ru) * 2013-08-02 2014-08-27 Государственное бюджетное образовательное Учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации (МГМСУ имени А.И. Евдокимова" Минздрава России) Способ персонифицированной профилактики эстрогензависимых заболеваний у здоровых женщин и женщин с факторами сердечно-сосудистого риска в возрасте 45-60 лет
CA2989975C (en) 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight

Also Published As

Publication number Publication date
NZ739195A (en) 2024-04-26
MY187233A (en) 2021-09-13
CN113750108A (zh) 2021-12-07
HRP20240121T1 (hr) 2024-04-12
LT3313408T (lt) 2024-03-12
MX389310B (es) 2025-03-20
EP3313408B1 (en) 2023-12-06
KR102217942B1 (ko) 2021-02-19
JP2018527305A (ja) 2018-09-20
BR112017028048A2 (pt) 2018-09-04
ZA201800067B (en) 2019-07-31
EA201792595A1 (ru) 2018-06-29
EP3313408A1 (en) 2018-05-02
MX2017016801A (es) 2018-05-11
DK3313408T3 (da) 2024-01-29
AU2016282863B2 (en) 2021-05-27
PH12017502379A1 (en) 2018-06-25
HK1255216A1 (zh) 2019-08-09
EA036497B1 (ru) 2020-11-17
PL3313408T3 (pl) 2024-04-15
FI3313408T3 (fi) 2024-01-25
CA2989975C (en) 2021-10-12
AU2016282863A1 (en) 2018-02-08
KR20180019173A (ko) 2018-02-23
CN113750108B (zh) 2025-08-19
NI201700173A (es) 2018-04-02
JP6827962B2 (ja) 2021-02-10
CN108025014A (zh) 2018-05-11
RS65196B1 (sr) 2024-03-29
CA2989975A1 (en) 2016-12-29
SI3313408T1 (sl) 2024-04-30
HRP20240121T8 (hr) 2024-05-10
WO2016207298A1 (en) 2016-12-29
UA122873C2 (uk) 2021-01-13
ES2970532T3 (es) 2024-05-29
CN108025014B (zh) 2021-10-22
SMT202400062T1 (it) 2024-03-13
HUE065350T2 (hu) 2024-05-28

Similar Documents

Publication Publication Date Title
SV2017005602A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
UY35293A (es) Isotiazoles sustituidos con amino
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2016001422A (es) Composicion farmaceutica de fingolimod.
CY1118287T1 (el) Χρηση αλατων βολφραμιου (vi) για την θεραπεια γυναικειας ελλειψης γονιμοτητας σε μη-διαβητικα θηλαστικα
CL2016000397A1 (es) Tratamiento contra el cáncer
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido
UY36474A (es) Método para producir liposomas que contienen un ingrediente farmacéutico activo